Enfusion Inc

Enfusion — Q3 2023 Earnings Presentation

20 slides from Enfusion's earnings presentation, Nov 7, 2023

  1. Slide 1: Enfusion 3Q 2023 Shareholder Letter

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. ©2023 ENFUSION. ALL RIGHTS RESERVED. Enfusion 3Q 2023 Shareholder Letter November 2023

  2. Slide 2: Disclaimer: Forward-Looking Statements

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Disclaimer 2 Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933 (

  3. Slide 3: Dear Shareholders

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 3 Dear Shareholders, Enfusion delivered another solid performance in the third quarter. Our results exceeded our expectations and demonstrated the durability of our model and our ability to improve our Adjusted EBITDA margins despite

  4. Slide 4: Our mission

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. To help solve investment managers’ evolving business and operational challenges through next generation technology Our mission 4

  5. Slide 5: We simplify and unify the investment management lifecycle

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. …empowering teams to operate in concert CFO COO CIO Portfolio Manager Analysts Traders Compliance Officer Investor Relations Middle Office Back Office We simplify and unify the investment management lifecycle We manage complex workflo

  6. Slide 6: Serving clients across the investment management industry

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 6 Serving clients across the investment management industry Alternative Investment Managers Hedge Funds Private Equity Private Credit Family Offices Institutional Investment Managers Wealth Managers Traditional Asset Managers Mutual F

  7. Slide 7: Purpose-built end-to-end solution

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Purpose-built end-to-end solution 7 Portfolio Management System Order Execution Management System Technology-Powered Services Accounting / General Ledger Analytics • Live details of portfolio positions • Real-time Investment Book of R

  8. Slide 8: Addressing a large and growing market

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Robust growth in Underlying industry Addressing a large and growing market $11.5bn $5.7bn $2.0bn $19bn+ Software & IT services from Investment Management Internal IT spend IT hardware spend Source: IDC’s Worldwide Capital Markets IT S

  9. Slide 9: Client-centric approach: Why we win

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 9 Client-centric approach Why we win One end-to-end solution, one single dataset and source of truth Rapid pace of delivery and evolution Open, flexible and tailored Unique ability to lead with a single solution – and then adjust to a

  10. Slide 10: Q3 2023 key financial highlights

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Q3 2023 key financial highlights $44.4 13.3% YoY Growth Adjusted Free Cash Flow Z00 Total Revenue Z00 Adjusted EBITDA Z00 115.7% FCF Conversion $9.5 $29.9 67.3% Gross Margin Highly attractive SaaS model with combination of scale, grow

  11. Slide 11: Strong growth trends with ongoing profitability

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Strong growth trends with ongoing profitability Operating Cash Flow and Adjusted Free Cash Flow $ in millions $39.2 $40.5 $41.0 $42.7 $44.4 3Q22 4Q22 1Q23 2Q23 3Q23 Revenue Gross Profit and Adjusted Gross Profit 34.8% 27.2% 20.0% 69.4

  12. Slide 12: Organic, sticky expansion at scale

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. $158.7 $164.7 $167.0 $171.2 $177.9 3Q22 4Q22 1Q23 2Q23 3Q23 116.6% 115.4% 110.5% 106.1% 107.1% 3Q22 4Q22 1Q23 2Q23 3Q23 Organic, sticky expansion at scale 12 Net Dollar Retention Rate(1) Avg Contract Value 810 819 813 827 842 3Q22 4Q2

  13. Slide 13: Appendix

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Appendix

  14. Slide 14: Consolidated Balance Sheets

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 14 ENFUSION, INC. CONSOLIDATED BALANCE SHEETS (dollars and shares in thousands, except par value) ASSETS Current assets: Cash and cash equivalents $ 31,652 $ 62,545 Accounts receivable, net 24,855 25,855 Prepaid expenses 4,079 6,105 O

  15. Slide 15: Consolidated Statements of Operations

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 15 ENFUSION, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (dollars and shares in thousands, except per share amounts) (Unaudited) REVENUES: Platform subscriptions $ 40,857 $ 35,953 Managed services 3,028 2,504 Other 472 694 Total revenu

  16. Slide 16: Consolidated Statements of Cash Flows

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 16 ENFUSION, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (dollars in thousands) (Unaudited) Cash flows from operating activities: Net income (loss) $ 8,353 $ (14,051) Adjustments to reconcile net income (loss) to net cash provided by o

  17. Slide 17: Reconciliations To Non-GAAP Financial Measures

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures 17 The following table reconciles net income to adjusted EBITDA: The following table reconciles gross profit to adjusted gross profit: ($ in thousands) September 30, 2022 December 31, 202

  18. Slide 18: Reconciliations To Non-GAAP Financial Measures

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures 18 The following table reconciles operating cash flow to adjusted free cash flow: The Company’s stock-based compensation expense was recognized in the following captions within the consol

  19. Slide 19: Definitions: Non-GAAP Financial Measures

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 19 Definitions Non-GAAP Financial Measures In addition to financial measures prepared in accordance with GAAP, this presentation and the accompanying tables include Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, Adjus

  20. Slide 20: Definitions Continued: Key Metrics

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 20 Definitions Continued Key Metrics: In connection with the management of our business, we identify, measure and assess a variety of key metrics. The key metrics we use in managing our business are set forth below. Annual Recurring R

Enfusion — Q3 2023 Earnings Presentation on 6ix